StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Edwards Lifesciences Corporation logo

Edwards Lifesciences Corporation

EW · ARCX · Medical Devices · United States

Market Capitalization47.91B USD
Trailing P/E45.90 USD
52-Week Change13.52 USD
Beta0.9340 USD

Edwards Lifesciences Corporation is the leading global structural heart innovation company, specializing in patient-focused medical devices for structural heart disease, critical care, and surgical monitoring. The company develops and commercializes breakthrough technologies, including pioneering transcatheter aortic valve replacement (TAVR) systems and hemodynamic monitoring solutions, to address unmet needs in cardiovascular care through minimally invasive procedures. Its product portfolio encompasses heart valve therapies and monitoring systems that enhance patient outcomes and quality of life. Edwards Lifesciences Corporation collaborates with leading clinicians and researchers worldwide to deliver innovations in structural heart procedures, such as TAVR and mitral platforms, alongside critical care technologies. These offerings serve healthcare providers globally, emphasizing structural heart disease management and procedural efficiency. Founded in 2000 and headquartered in Irvine, California, Edwards Lifesciences Corporation plays a pivotal role in the medical device industry by advancing cardiovascular solutions and supporting clinical advancements in heart care.

Industry

Medical Devices

Healthcare sector · United States

Stories

Structural patterns identified in Edwards Lifesciences Corporation

No stories identified yet.

Key Metrics

Market Capitalization
47.91BUSD
NormalMar 21, 2026
Trailing P/E
45.90USD
AboveNormalMar 21, 2026
Revenue (TTM)
6.07BUSD
NormalMar 21, 2026
Profit Margin
17.69%
NormalMar 21, 2026
Beta
0.9340USD
NormalMar 21, 2026
52-Week Change
13.52USD
ExtremeMar 21, 2026

This company does not currently pay dividends.

Valuation9
Market Capitalization
47.91BUSD
NormalMar 21, 2026
Enterprise Value
44.46BUSD
NormalMar 21, 2026
Trailing P/E
45.90USD
AboveNormalMar 21, 2026
Forward P/E
25.13USD
NormalMar 21, 2026
PEG Ratio
-0.6088USD
ExtremeMar 21, 2026
Price to Sales (TTM)
7.95USD
NormalMar 21, 2026
Price to Book (MRQ)
4.67USD
NormalMar 21, 2026
Enterprise to Revenue
7.33USD
NormalMar 21, 2026
Enterprise to EBITDA
24.77USD
NormalMar 21, 2026
Profitability & Growth17
Gross Margin
78.15%
NormalMar 21, 2026
Profit Margin
17.69%
NormalMar 21, 2026
Operating Margin
23.70%
NormalMar 21, 2026
Return on Assets (TTM)
0.0765USD
NormalMar 21, 2026
Return on Equity (TTM)
0.1035USD
NormalMar 21, 2026
Revenue (TTM)
6.07BUSD
NormalMar 21, 2026
Revenue per Share (TTM)
10.38USD
NormalMar 21, 2026
Quarterly Revenue Growth
0.1330USD
NormalMar 21, 2026
Gross Profit (TTM)
4.73BUSD
NormalMar 21, 2026
EBITDA
1.96BUSD
ExtremeMar 21, 2026
Net Income (TTM)
1.06BUSD
NormalMar 21, 2026
Quarterly Earnings Growth (YoY)
-0.7630USD
BelowNormalMar 21, 2026
Operating Cash Flow (TTM)
1.60BUSD
NormalMar 21, 2026
Levered Free Cash Flow (TTM)
1.17BUSD
NormalMar 21, 2026
Trailing Annual Dividend Rate
0.00USD
NormalMar 21, 2026
Trailing Annual Dividend Yield
0.00%
NormalMar 21, 2026
Payout Ratio
0.00USD
NormalMar 21, 2026
Financial Strength13
Shares Outstanding
580.70MShares
NormalMar 21, 2026
Float Shares
579.03MUSD
NormalMar 21, 2026
Shares Short
12.38MShares
NormalMar 21, 2026
Short Ratio
2.46USD
NormalMar 21, 2026
Short % of Shares Outstanding
0.0242USD
NormalMar 21, 2026
% Held by Insiders
0.0092USD
NormalMar 21, 2026
% Held by Institutions
0.9155USD
NormalMar 21, 2026
Total Cash (MRQ)
4.23BUSD
NormalMar 21, 2026
Total Cash per Share (MRQ)
7.28USD
NormalMar 21, 2026
Total Debt (MRQ)
705.40MUSD
NormalMar 21, 2026
Total Debt to Equity (MRQ)
6.82USD
AboveNormalMar 21, 2026
Current Ratio (MRQ)
3.72USD
AboveNormalMar 21, 2026
Book Value per Share (MRQ)
17.80USD
NormalMar 21, 2026
Market & Technical9
52-Week Low
65.94USD
NormalMar 21, 2026
52-Week High
87.89USD
NormalMar 21, 2026
52-Week Change
13.52USD
ExtremeMar 21, 2026
Beta
0.9340USD
NormalMar 21, 2026
50-Day MA
82.54USD
NormalMar 21, 2026
200-Day MA
80.37USD
NormalMar 21, 2026
Avg 10-Day Volume
4.24MUSD
NormalMar 21, 2026
Avg 30-Day Volume
5.08MUSD
NormalMar 21, 2026
Diluted EPS (TTM)
1.81USD
NormalMar 21, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.